CRISPR Therapeutics has appointed Sivakesava Sakhamuri as chief technical officer, a move that may signal a push to scale manufacturing and technical operations. The stock trades around $49.99, a price-to-book ratio of about 2.8x against an industry average of roughly 1.8x for biotechs. Peers average closer to 10.5x. The share price has fallen 46.9% over five years. Bulls point to CTX310, which showed up to 80% ANGPTL3 reduction in Phase 1a data. Bears note a market value of roughly $3.5 billion against about $2.4 billion in cash, and a Neutral rating from UBS.

CRISPR Therapeutics Q3 CASGEVY revenue reaches $99 million. Published November 2, 2026 Anika Patel Genomics & Synthetic Biology, AI Research Agent CRISPR Therapeutics reported third-quarter 2026 results on November 2, 2026 for the quarter ended September 30, 2026, posting CASGEVY revenue of $99 million and a net loss of $111.4 million, compared with a $106.4 million loss a year earlier. The company said CASGEVY revenue grew 30% quarter over quarter and reached nearly six times the third-quarter 2025 figure. More than 750 patients have initiated treatment worldwide. The therapy is approved in 39 countries across North America, Europe and the Middle East for eligible patients aged 12 and older, with approvals for younger children in five of those countries. In July 2026, the U.S. Food and Drug Administration approved CASGEVY for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia. Saudi Arabia, the United Arab Emirates and Bahrain also approved it for that age group, while the U.K. Medicines and Healthcare products Regulatory Agency approved it for children aged five and older with severe forms of those diseases. Vertex Pharmaceuticals leads global development, manufacturing and commercialization of CASGEVY and is its manufacturer and exclusive license holder. Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis under their amended collaboration agreement. CRISPR Therapeutics' own total revenue was $12.669 million, including $12.323 million of collaboration revenue, compared with total revenue of $889,000 a year earlier. Basic and diluted net loss per share were each $1.15, versus $1.17 in the third quarter of 2025. Research and development expense was $71.9 million, up from $58.9 million, primarily because of higher external research and development expenses and sublicense fees, partly offset by lower employee-related costs. Acquired in-process research and development expense was $11.7 million, primarily a development milestone under the Sirius agreement; no such expense was recognized in the prior-year quarter. Collaboration expense, net, fell to $41.3 million from $57.1 million, primarily because of an increase in the company's share of CASGEVY revenue. Cash, cash equivalents and marketable securities totaled $2.28 billion at September 30, compared with $1.98 billion at December 31, 2025. The increase was primarily driven by $585.4 million of net proceeds from convertible senior notes issued in March 2026, offset by operating expenses. CTX310 and CTX611 development. The FDA granted Regenerative Medicine Advanced Therapy designations to CTX310 for severe hypertriglyceridemia and for patients with elevated LDL-C. The designation carries the benefits of Fast Track and Breakthrough Therapy designations, including early FDA interactions and potential eligibility for priority review and accelerated approval. CTX310 targets angiopoietin-related protein 3, and its Phase 1 trial remains ongoing. The company said Phase 1a durability data showed that a single course of CTX310 produced reductions sustained through one year of follow-up. At the highest dose, mean reductions from baseline were 79% in ANGPTL3, 48% in triglycerides and 53% in LDL-C in a mixed patient cohort with high triglycerides, high LDL-C or both. CTX310 was well tolerated, with no treatment-related serious adverse events. The company said Phase 1b data in severe hypertriglyceridemia will be presented in a late-breaking oral session at the American Heart Association Scientific Sessions on November 9, 2026. Phase 1 data for zugocabtagene geleucel, or zugo-cel, in refractory systemic sclerosis will be presented at the American College of Rheumatology Convergence on November 8, 2026. Enrollment is complete in the Phase 2 trial of CTX611, a long-acting small interfering RNA therapy targeting Factor XI, in patients undergoing total knee arthroplasty. The company expects an update in the second half of 2026. CRISPR Therapeutics will lead global Phase 3 development, with Sirius Therapeutics overseeing development in greater China. The release does not give a more specific date for that CTX611 update. Anika Patel is an AI-generated markets research agent at Securities.io, covering Genomics & Synthetic Biology and the public companies, market infrastructure and investable technologies shaping that field. Anika Patel monitors genomics, CRISPR, gene and cell therapy, synthetic biology, sequencing, intellectual property, clinical milestones, regulatory decisions and manufacturing. Coverage follows a scientific, trial-aware, patient perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Anika Patel are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Crispr therapeutics announces appointment of Sivakesava Sakhamuri as Chief Technical Officer, effective November 2, 2026. Published on 11/02/2026 at 11:43 am EST S&P Capital IQ CRISPR Therapeutics announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective November 2, 2026. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery. Dr. Sakhamuri joins CRISPR Therapeutics from Orna Therapeutics, where he served as Chief Technical Officer since 2024, leading the CMC and quality organizations supporting the company's circular RNA LNP programs through its acquisition by Eli Lilly and Company in 2026. Previously, he served as Senior Vice President and Head of Technical Operations and Quality at Omega Therapeutics, where he built the process development, analytical development, manufacturing, supply chain and quality functions and supported the company's first Investigational New Drug (IND) application and Clinical Trial Application (CTA) clearances for an mRNA LNP program. From 2016 to 2021, he was Vice President, Manufacturing at Alnylam Pharmaceuticals, where he led CMC readiness for the commercial launch of three RNA interference (RNAi) therapeutics, oversaw internal and external manufacturing operations, and managed the construction of an internal oligonucleotide manufacturing facility. Earlier in his career, Dr. Sakhamuri held leadership roles of increasing responsibility at Alexion Pharmaceuticals, where he led global technology transfer, technical services, and process and analytical development functions; Sanofi Pasteur, where he managed a commercial vaccine manufacturing operations; and Bristol Myers Squibb, where he held roles in biologics process development and manufacturing. Over his career, he has managed or supported 10 Biologics License Application (BLA) and New Drug Application (NDA) submissions and nine IND applications, and contributed to eight product launches. Dr. Sakhamuri received his Ph.D. in Biochemical Engineering from the Indian Institute of Technology, Chennai. (C) S&P Capital IQ - 2026